Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_assertion type Assertion NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_head.
- NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_assertion description "[Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_provenance.
- NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_assertion evidence source_evidence_literature NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_provenance.
- NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_assertion SIO_000772 25175099 NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_provenance.
- NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_assertion wasDerivedFrom befree-2016 NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_provenance.
- NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_assertion wasGeneratedBy ECO_0000203 NP1215605.RApMjNIMTmmMezMFviYMlXsqV7fUcDZ6-XQNIl66eU_Gg130_provenance.